TransEnterix Announces $31.25 Million Registered Direct Offering of Common Stock
A shelf registration statement on Form S-3 (File No. 333-236200) relating to the registered direct offering of the shares of common stock described above was filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
This press release includes statements relating to the registered direct offering of common stock and expected proceeds receivable by us. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include market and other conditions and statements regarding the consummation of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds from the registered direct offering; whether we will be able to continue to progress our strategic plan in 2021; whether and the jurisdictions where the Senhance Surgical System is available for sale provides an opportunity to grow Senhance Surgical System placements and sales, including in